Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), which focuses on central nervous disorders conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy,

Benzinga15:06 ET

Needham Starts Axsome at Buy, Cites Revenue Growth Potential

Seeking Alpha13:58 ET

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (

Benzinga13:04 ET

Alnylam Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -6.83% Cantor Fitzgerald $150 → $220 Maintains Neutral 07/12/2024 8% Morgan Stanley $250 → $255

BenzingaJul 22 11:18 ET · Ratings

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had

BenzingaJul 21 09:57 ET

Russell Rotation: YTD Market Capitalizations Swelling for Small-caps

Seeking AlphaJul 19 18:08 ET